It's pretty common to see a biotech tank on any given day, so when three companies dropped substantially the other day, it wasn't that surprising. Unless you're an investor in the companies, of course.
Seattle Genetics (NASDAQ:SGEN), which sells cancer drug Adcetris, dropped because revenue was only up 19%. While that wasn't exactly the growth investors were hoping for, Seattle Genetics still has a substantial pipeline worth owning.
Pharmacyclics (NASDAQ:PCYC) was another earnings "loser." During the first full quarter on the market, demand for its cancer drug, Imbruvica, came in at a little over $50 million. Despite getting a second approval in mid February for CLL, which is a larger market than mantle cell lymphoma that it was first approved for, Pharmacyclics guided for sales of just $295 million for the year.
Finally, Endocyte (NASDAQ:ECYT) was the loser of the group after announcing that its trial testing vintafolide in ovarian-cancer patients was stopped early for futility. Based on data to date, the data monitoring committee believes the trial won't be able to show that vintafolide increases in progression-free survival if Endocyte let it go to completion.
In the video below, senior biotech specialist Brian Orelli and health care analyst David Williamson discuss the drops and which companies might be bad-news buys.
Brian Orelli and David Williamson have no positions in any stocks mentioned. The Motley Fool recommends Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Seattle Genetics, Inc. Fell Today
Investors aren't particularly excited about data presented at the American Society of Hematology meeting.
Immunomedics' Data Is Good News for Seattle Genetics, Too
Seattle Genetics could do handsomely following positive midstage study results for Immunomedics' lead drug.
Market-Moving News Is on Tap for Seattle Genetics
Full study results will be released at a high-profile conference this month.